Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 0.43 |
| ▸ | CDK2 | P24941 | 15/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163727 | 0.89 | CDK1 (0.47) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5164037 | 0.89 | CDK1 (0.47) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5166861 | 0.89 | CDK1 (0.47) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5166259 | 0.87 | CDK1 (0.45) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5167086 | 0.86 | CDK1 (0.41) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5163995 | 0.83 | CDK1 (0.41) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5164232 | 0.83 | CDK1 (0.42) | CDK1CDK2IKBKBCHUKKCNH2 | |
| SCHEMBL5167012 | 0.83 | IKBKB (0.45) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5164224 | 0.81 | IKBKB (0.41) | CDK1CDK2IKBKBCHUK | |
| SCHEMBL5164982 | 0.81 | IKBKB (0.40) | CDK1CDK2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | claimed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | claimed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | CNKSR1, IL1RN, CHUK | CDK1 242/4885CDK2 159/4885IKBKB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.